1. Home
  2. Live Updates
  3. Peter schmid

Live Breaking News & Updates on Peter schmid

Stay informed with the latest breaking news from Peter schmid on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Peter schmid and stay connected to the pulse of your community

Schmid Summarizes Updates in HER2-Positive Breast Cancer Management

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

London , City-of , United-kingdom , San-antonio , Texas , United-states , Megan-hollasch , Peter-schmid , Twitter , Linkedin , Facebook , Genentech

PUMA's Sneaker Archive Is Truly Wild

PUMA's sneaker archive is filled with left-field shoes that are starting to get the attention they deserve. We deep-dived into some of its most wild sneakers.

Germany , New-york , United-states , Japan , Sono , Okinawa , German , Yutori-fuyu , Peter-schmid , Tung-hoang , Ray-horacek , Puma-mikoshi

Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

San-antonio , Texas , United-states , Peter-schmid , Barts-breast-cancer-centre , Eastern-cooperative-oncology-group , Centre-of-eand , Oncology-nursing , Antonio-breast-cancer , Cancer-medicine , Antonio-breast-cancer-symposium , Event-free-survival

Biometrics, digital ID advisory board changes announced in Scotland, US, Germany

Biometrics and digital ID security companies in the U.S. and Germany have announced the appointment of new members to advisory roles.

United-kingdom , Germany , United-states , American , German , Arun-vemury , Mark-johnson , Augentic-gmb , Klaus-joachim-krauth , Peter-schmid , Fraser-sampson , Brian-plastow

Conference Highlights from SABCS

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

San-antonio , Texas , United-states , American , Peter-schmid , Aptneo-michelangelo , American-society-of-hematology-annual-meeting , San-antonio-breast-cancer-symposium , American-society , Hematology-annual , Sibylle-loibl , Sabcs

Keytruda, Chemo Show Early-Stage Breast Cancer Event-Free Survival Benefits

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer.

San-antonio , Texas , United-states , Peter-schmid , Barts-breast-cancer-centre , Antonio-breast-cancer , Breast-cancer , Sabcs ,

Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer. 

Peter-schmid , Centre-of-experimental-cancer-medicine , Breast-cancer-centre , Academic-breast-cancer-programme , Barts-cancer-institute , Queen-mary-university , Cancer-medicine , Experimental-cancer-medicine , Nct03036488 , Keynote-522-trial , D , Hd

EFS Benefit With Neoadjuvant Pembrolizumab/Chemo Combo, Adjuvant Pembrolizumab Upheld in High-Risk Early TNBC

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

San-antonio , Texas , United-states , Christabel-wilson , Daiichi-sankyo , Astellas-pharma , Peter-schmid , Pfizer , Novartis , Barts-breast-cancer-centre , Genentech , Boehringer-ingelheim

Dato-DXd Plus Durvalumab Elicits Durable Responses in Metastatic TNBC Regardless of PD-L1 Status

Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.

London , City-of , United-kingdom , Peter-schmid , Centre-of-experimental-cancer-medicine , Experimental-cancer-medicine , Barts-breast-cancer-centre , Barts-cancer-institute , Datopotamab-deruxtecan , Breast-cancer , Tnbc , Triple-negative-breast-cancer

Rapid City's rental riddle: Short-term rental surge comes amid housing crunch

In the picturesque Black Hills region Peter Schmid is capitalizing on a lucrative trend in the housing market by offering short-term rentals in Rapid City.

Black-hills , South-dakota , United-states , Rapid-city , Pennington-county , Brittney-molitor , Peter-schmid , Laura-jones , Vicki-fisher , Elevate-rapid-city , Brook-kaufman